High-purity synthetic peptides, documented to the lot.
Tessellix supplies synthetic peptide materials to laboratory and research buyers in the United States. Every lot ships against a certificate of analysis establishing identity and purity.
Research use only · Not for human consumption
Format shown for illustration. Certificates are lot-specific and issued by the analyzing laboratory.
Quality and documentation
Documentation is the product.
Research material is only as useful as what is known about it. Our sourcing and record-keeping are built so that a buyer can establish what a given vial contains, which lot it came from, and how that was determined.
Lot-level certificates
Identity and purity are established per lot, not per product line. Certificates are retained on file and provided to account holders on request; direct linkage to each product record in the portal is in progress.
Specified sourcing
Material is manufactured to our specification by third-party suppliers. We are a distributor and do not manufacture or compound.
Consistent labeling
Every unit carries research-use-only labeling. Storage and handling information ships with the material.
Research use policy
A narrow business, deliberately.
Material supplied by Tessellix is for laboratory research. That is not a disclaimer bolted onto a broader business — it is the boundary of the business itself.
Determining whether a material is appropriate and lawful for a given research application is the responsibility of the purchasing investigator and their institution.
What we do not do
- We do not manufacture or compound.
- We do not dispense, prescribe, or sell prescription drugs.
- We do not handle controlled or scheduled substances.
- We do not publish dosing guidance or administration protocols.
- We do not make therapeutic, diagnostic, or disease-treatment claims, and we do not market material as a drug, dietary supplement, or cosmetic.
Regulatory
We track the federal record, and publish it plainly.
Research peptides sit inside an active federal review. Our customers ask about it, and an accurate public record is more useful than the commentary that otherwise fills the gap.
Current status, in one line
In July 2026 an FDA advisory committee recommended six of seven nominated peptides for the Section 503A Bulk Drug Substances List. The recommendation is advisory and non-binding. No rulemaking has occurred, and none of these substances is an FDA-approved drug.
Read the full recordAccounts
Catalog and pricing are held in the portal.
Tessellix operates on an account basis. Available materials, certificates of analysis, and pricing are shown to account holders after sign-in — the standard arrangement for a research-materials supplier, and the reason there is no public catalog here.
Wound Concierge LLC, operating as Tessellix · info@tessellix.com
